Evaluation of Serum Farnesoid X Receptor (FXR) Levels and Their Correlation with Metabolic Parameters Related to Obesity: A Clinical Investigation - Takeaways - MDSpire

Evaluation of Serum Farnesoid X Receptor (FXR) Levels and Their Correlation with Metabolic Parameters Related to Obesity: A Clinical Investigation

  • By

  • Zeyneb Irem Yuksel Salduz

  • Rana Turgut

  • Zeynep Seval Coskun

  • Ozge Pasin

  • Murat Kartal

  • Aclan Ozder

  • April 15, 2026

  • 0 min

Share

  • 1

    Obesity is a leading cause of mortality, with projections indicating that 57.8% of the global population may be overweight or obese by 2030.

  • 2

    The Farnesoid X Receptor (FXR) plays a critical role in bile acid and cholesterol homeostasis, influencing glucose and lipid metabolism.

  • 3

    Research indicates that FXR activation can improve metabolic diseases by reducing lipogenesis and enhancing fatty acid oxidation.

  • 4

    This study is the first to investigate the association between serum FXR levels and BMI in healthy and obese individuals.

  • 5

    Findings may lead to new therapeutic strategies for obesity by selectively modulating serum FXR levels.

Original Source(s)

Evaluation of Serum Farnesoid X Receptor (FXR) Levels and Their Correlation with Metabolic Parameters Related to Obesity: A Clinical Investigation

  • by Zeyneb Irem Yuksel Salduz, Rana Turgut, Zeynep Seval Coskun, Ozge Pasin, Murat Kartal, Aclan Ozder

  • April 15, 2026

Related Content

The immunometabolic mechanisms and therapeutic targets of metabolic dysfunction-associated steatohepatitis

NIH researchers identify avenue for enhanced GLP-1-induced weight loss

  • May 22, 2026

Effect of weight loss intervention on assisted reproductive outcomes in women with obesity and infertility: a retrospective cohort study